Evidence map›Paper›PMID 33363374›Full record

ArticleInternational journal of nanomedicine2020

Polydopamine Nanoparticles Camouflaged by Stem Cell Membranes for Synergistic Chemo-Photothermal Therapy of Malignant Bone Tumors.

Meng Zhang, Fuqiang Zhang, Te Liu, Pu Shao, Lian Duan, Jun Yan, Xupeng Mu, Jinlan Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 72 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Meng ZhangScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Fuqiang ZhangScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Te LiuScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Pu ShaoScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Lian DuanScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Jun YanScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Xupeng Mu *Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Jinlan Jiang *Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Jilin University · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNanoparticle (NP)-based chemo-photothermal therapy (CPT) has been shown to be a promising non-invasive approach for antitumor treatment. However, NPs must overcome the limitations of opsonization, clearance of the reticuloendothelial system, and ineffective targeting of tumor tissue sites. To solve these problems, stem cell membrane (SCM)-camouflaged polydopamine nanoparticles (PDA@SCM NPs) carrying the hydrophobic anticancer drug 7-ethyl-10-hydroxycamptothecin (SN38) were constructed for CPT of malignant bone tumors.

methodsWe developed umbilical-cord mesenchymal stem cell membrane-coated polydopamine nanoparticles encapsulating SN38 (PDA-SN38@SCM NPs) as an efficient tumor-targeting drug-delivery platform for CPT of malignant bone tumors. We characterized PDA@SCM NPs and evaluated the biocompatibility and anti-phagocytosis properties of PDA@SCM NPs. The antitumor activity of PDA-SN38@SCM NPs was evaluated in MG63 lines and an MG63 xenograft model in mice.

resultsSynthesized PDA-SN38@SCM NPs retained an excellent photothermal effect after SN38 loading. The drug release of PDA-SN38@SCM NPs could be triggered by near-infrared irradiation and an acidic stimulus. PDA@SCM NPs exhibited lower nonspecific macrophage uptake, longer retention in blood, and more effective accumulation at tumor sites than that shown by PDA NPs. Confocal laser scanning microscopy (CLSM) and flow cytometry showed that MG63 cells took up more PDA-SN38@SCM NPs than PDA-SN38 NPs. In vitro and in vivo antitumor studies demonstrated the outstanding performance of PDA-SN38@SCM NPs in synergistic CPT for bone tumors.

conclusionPDA-SN38@SCM NPs demonstrated an extraordinary synergistic CPT effect and could be a promising strategy for the treatment of malignant bone tumors.

Indexed as

Photothermal TherapyAnimalsAntineoplastic AgentsBiocompatible MaterialsBone NeoplasmsCell Line, TumorCell MembraneDrug LiberationFemaleHumansImmune EvasionIndolesIrinotecanMiceMice, Inbred BALB CMice, NudeAntineoplastic AgentsBiocompatible MaterialsIndolesIrinotecanpolydopaminePolymerschemo-photothermal therapypolydopamine nanoparticlesstem cell membrane

Identifiers

PMID33363374
PMCPMC7754090
OpenAlexW3110669486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.